(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Zynga, Alberton Acquisition Corporation, and Tilray.

Rank Financial Asset Price Change Updated (EST)
1 Zynga (ZNGA) 8.44 40.67% 2022-01-13 13:31:02
2 Alberton Acquisition Corporation (ALACR) 0.47 33.98% 2022-01-13 13:06:06
3 Tilray (TLRY) 7.29 13.55% 2022-01-13 09:47:54
4 Moderna (MRNA) 233.70 9.28% 2022-01-13 13:32:48
5 BioNTech SE (BNTX) 230.00 8.57% 2022-01-13 13:39:41
6 NeuroMetrix (NURO) 5.06 7.66% 2022-01-13 10:36:18
7 Coupons.com (COUP) 147.66 7.3% 2022-01-13 13:31:40
8 Vericel Corporation (VCEL) 38.94 6.74% 2022-01-12 22:07:20
9 Novavax (NVAX) 134.99 6.54% 2022-01-13 15:43:19
10 Bilibili (BILI) 40.89 6.37% 2022-01-13 13:39:38

The three most active and biggest losers today are Amicus Therapeutics, Take-Two Interactive Software, and ATA Creativity Global.

Rank Financial Asset Price Change Updated (EST)
1 Amicus Therapeutics (FOLD) 9.45 -17.18% 2022-01-13 10:56:43
2 Take-Two Interactive Software (TTWO) 142.99 -13.13% 2022-01-13 15:44:42
3 ATA Creativity Global (AACG) 2.01 -12.23% 2022-01-13 09:06:06
4 AGBA Acquisition Limited (AGBAR) 0.15 -11.59% 2022-01-13 11:08:06
5 Celsius Holdings (CELH) 49.71 -8.96% 2022-01-13 13:31:38
6 Accolade (ACCD) 19.14 -8.51% 2022-01-13 09:09:50
7 VBI Vaccines (VBIV) 1.95 -8.02% 2022-01-12 21:07:17
8 XTL Biopharmaceuticals Ltd. (XTLB) 2.65 -7.71% 2022-01-13 07:41:06
9 Adial Pharmaceuticals (ADILW) 0.62 -7.48% 2022-01-13 10:07:18
10 Allakos (ALLK) 7.89 -7.39% 2022-01-13 13:10:06

Most Active Winners today

1. Zynga (ZNGA) – 40.67%

NASDAQ Composite ended the session with Zynga rising 40.67% to $8.44 on Thursday, after three successive sessions in a row of gains. NASDAQ Composite rose 0.05% to $14,942.83, after three sequential sessions in a row of gains, on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for Zynga is 326586000 which is 1008.74% above its average volume of 29455700.

Zynga’s last close was $9.15, 25.73% below its 52-week high of $12.32.

Zynga’s Sales

Zynga’s sales growth is 6% for the present quarter and 2.5% for the next. The company’s growth estimates for the current quarter is a negative 30% and positive 11.1% for the next.

Zynga’s Revenue

Year-on-year quarterly revenue growth grew by 59.4%, now sitting on 2.52B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Zynga’s stock is considered to be oversold (<=20).

Zynga’s Stock Yearly Top and Bottom Value

Zynga’s stock is valued at $8.44 at 16:32 EST, way under its 52-week high of $12.32 and way higher than its 52-week low of $5.57.

Zynga’s Moving Average

Zynga’s worth is way higher than its 50-day moving average of $7.04 and below its 200-day moving average of $9.16.

Previous days news about Zynga

  • Take-two interactive to buy Zynga in $12.7 billion deal. According to The Wall Street Journal on Monday, 10 January, "Take-Two Interactive Software Inc. has reached a deal to buy Zynga Inc. in a $12.7 billion deal that would unite two videogame companies with a presence across gaming platforms.", "The cash-and-stock deal would value mobile game maker Zynga at about $12.7 billion. "
  • Why this analyst thinks Zynga is A good deal for take-two interactive. According to Benzinga on Wednesday, 12 January, "Take-Two Interactive Software, Inc’s (NASDAQ:TTWO) intention to acquire FarmVille developer Zynga Inc (NASDAQ:ZNGA) is likely to "help smooth earnings variability while offering compelling synergy opportunities," according to BMO Capital Markets.", "The Take-Two Interactive Software Thesis: Although the company owns some iconic video games, it has not been able to leverage them onto mobile, and the Zynga acquisition "provides the capabilities to do so," Johnson said in the upgrade note."
  • Zynga soars 54% on take-two deal to buy the farmville creator for $12.7 billion. According to Business Insider on Monday, 10 January, "The agreement has a "go-shop" provision, giving Zynga and its board to February 24 to actively solicit, receive, and potentially enter negotiations with parties that offer other deal proposals."
  • Here's how much $100 invested in Zynga 5 years ago would be worth today. According to Benzinga on Monday, 10 January, "Buying $100 In ZNGA: 5 years ago, an investor could have purchased 37.45 shares of Zynga at the time with $100. "
  • Steve jobs told Zynga in-app purchases were 'stupid.' 15 years later, the 'farmville' creator lands biggest video game deal ever.. According to Benzinga on Tuesday, 11 January, "One of the biggest news items of the early new year Take-Two Interactive Software, Inc.’s (NASDAQ: TTWO) $12.7-billion acquisition of Zynga Inc (NASDAQ: ZNGA).", "I showed our iPhone Zynga Poker game to Steve Jobs and pitched him on allowing in-app purchase. "

More news about Zynga.

2. Alberton Acquisition Corporation (ALACR) – 33.98%

NASDAQ Composite ended the session with Alberton Acquisition Corporation rising 33.98% to $0.47 on Thursday while NASDAQ Composite rose 0.05% to $14,942.83.

Alberton Acquisition Corporation’s last close was $0.47, 0% below its 52-week high of $0.47.

Alberton Acquisition Corporation’s Stock Yearly Top and Bottom Value

Alberton Acquisition Corporation’s stock is valued at $0.47 at 16:32 EST, way below its 52-week low of $0.40.

More news about Alberton Acquisition Corporation.

3. Tilray (TLRY) – 13.55%

NASDAQ Composite ended the session with Tilray rising 13.55% to $7.29 on Thursday while NASDAQ Composite rose 0.05% to $14,942.83.

Volume

Today’s last reported volume for Tilray is 106000000 which is 326.18% above its average volume of 24871700.

Tilray’s last close was $7.15, 81.44% below its 52-week high of $38.53.

The company’s growth estimates for the ongoing quarter and the next is a negative 250% and a negative 200%, respectively.

Tilray’s Revenue

Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 513.08M for the twelve trailing months.

Tilray’s Stock Yearly Top and Bottom Value

Tilray’s stock is valued at $7.29 at 16:32 EST, below its 52-week low of $7.93.

Tilray’s Moving Average

Tilray’s worth is way under its 50-day moving average of $10.73 and way under its 200-day moving average of $14.96.

Previous days news about Tilray

  • Tilray results beat analyst target, shares rise. According to MarketWatch on Monday, 10 January, "Analysts expected Tilray to lose 9 cents a share on revenue of $170.5 million, according to a survey by FactSet. ", "The cannabis company is also changing its name to Tilray Brands Inc. Shares of Tilray rose 4.2% in premarket trades."
  • Tilray and budweiser maker AB inbev call off cannabis beverage partnership. According to Benzinga on Monday, 10 January, "When Tilray first announced the partnership in 2018, the two companies hadpledged to invest $50 million in the venture,called Fluent Beverage Co. Each company had a 50% ownership interest.", "We concluded our joint venture relationship with AB InBev," (…) "We retained the manufacturing equipment associated with CBD and THC beverages, obtained a royalty-free, perpetual, worldwide license to utilize the technology related to the manufacture of CBD and THC beverages, which was developed by the joint venture and negotiated a co-manufacturing arrangement to manufacture CBD beverages on behalf of Fluent," Tilray disclosed in a regulatory filing on Monday."
  • Tilray focuses on brand growth in saturated pot market. According to Bloomberg Quint on Monday, 10 January, "While competitors have recently lowered prices by around 23%, Tilray has only lowered its prices by about 2%, leaving it with more flexibility than other companies, he said.", "Only the strong will survive," said Blair MacNeil, president of Tilray Canada, on a conference call Monday. "
  • Tilray's revenue dives 8% qoq to $155m, announces new parent company name – tilray brands. According to Benzinga on Monday, 10 January, "The Canadian marijuana giant also announceda new parent name, Tilray Brands, Inc., reflecting the company’s evolution from a Canadian LPto a global consumer packaged goods companywith a portfolio of cannabis and lifestyle CPG brands."

More news about Tilray.

4. Moderna (MRNA) – 9.28%

NASDAQ Composite ended the session with Moderna jumping 9.28% to $233.70 on Thursday while NASDAQ Composite jumped 0.05% to $14,942.83.

Volume

Today’s last reported volume for Moderna is 17191500 which is 46.22% above its average volume of 11756600.

Moderna’s last close was $222.89, 55.2% under its 52-week high of $497.49.

Moderna’s Sales

Moderna’s sales growth is 8216.6% for the ongoing quarter and 1202.8% for the next. The company’s growth estimates for the present quarter and the next is 1694.9% and 1681.2%, respectively.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 6398.5%, now sitting on 7.02B for the twelve trailing months.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $233.70 at 16:32 EST, way under its 52-week high of $497.49 and way above its 52-week low of $102.66.

Moderna’s Moving Average

Moderna’s value is way under its 50-day moving average of $298.96 and way below its 200-day moving average of $267.83.

Previous days news about Moderna

  • Moderna inc (mrna) stock price and forecast: Moderna works on omicron booster. According to FXStreet on Tuesday, 11 January, "However, as more and more evidence mounted that Omicron appears less severe, Moderna has resumed the downtrend with the occasional spike as witnessed yesterday."
  • Singapore says virus deaths lowest among Moderna takers. According to Bloomberg Quint on Monday, 10 January, "Singapore saw the fewest deaths among those with the Moderna Inc. shot and the most among those with Sinovac Biotech Ltd.’s vaccine, as the city-state’s highly inoculated population provides a glimpse into how different immunizations are holding up in the real world. "
  • Moderna says it has $18.5 billion in vaccine orders for 2022. According to Bloomberg Quint on Monday, 10 January, "Analysts were expecting $19.3 billion in Moderna Covid vaccine sales for 2022, according to a Bloomberg survey of analyst estimates."
  • Moderna attempts to bounce off key support level: technical analysis. According to Benzinga on Monday, 10 January, "Throughout 2021 the company shipped approximately 807 million doses of the Moderna COVID-19 vaccine. ", "About 25% of all doses went to low and middle income countries through direct sales by Moderna and donations from high income countries."

More news about Moderna.

5. BioNTech SE (BNTX) – 8.57%

NASDAQ Composite ended the session with BioNTech SE rising 8.57% to $230.00 on Thursday, after two consecutive sessions in a row of gains. NASDAQ Composite rose 0.05% to $14,942.83, after three consecutive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for BioNTech SE is 3737690 which is 12.82% above its average volume of 3312810.

BioNTech SE’s last close was $220.87, 52.4% under its 52-week high of $464.00.

The company’s growth estimates for the current quarter and the next is 1188.8% and 438%, respectively.

BioNTech SE’s Revenue

Year-on-year quarterly revenue growth grew by 12630.2%, now sitting on 7.77B for the twelve trailing months.

BioNTech SE’s Stock Yearly Top and Bottom Value

BioNTech SE’s stock is valued at $230.00 at 16:32 EST, way below its 52-week high of $464.00 and way above its 52-week low of $80.55.

BioNTech SE’s Moving Average

BioNTech SE’s worth is way below its 50-day moving average of $269.93 and way under its 200-day moving average of $268.56.

More news about BioNTech SE.

6. NeuroMetrix (NURO) – 7.66%

NASDAQ Composite ended the session with NeuroMetrix jumping 7.66% to $5.06 on Thursday, after four successive sessions in a row of gains. NASDAQ Composite rose 0.05% to $14,942.83, after three successive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for NeuroMetrix is 356575 which is 0.6% above its average volume of 354446.

NeuroMetrix’s last close was $5.26, 86.43% below its 52-week high of $38.75.

NeuroMetrix’s Revenue

Year-on-year quarterly revenue growth declined by 0.8%, now sitting on 7.36M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

NeuroMetrix’s stock is considered to be oversold (<=20).

NeuroMetrix’s Stock Yearly Top and Bottom Value

NeuroMetrix’s stock is valued at $5.06 at 16:32 EST, way below its 52-week high of $38.75 and way higher than its 52-week low of $1.90.

NeuroMetrix’s Moving Average

NeuroMetrix’s worth is way below its 50-day moving average of $8.84 and way below its 200-day moving average of $6.85.

More news about NeuroMetrix.

7. Coupons.com (COUP) – 7.3%

NASDAQ Composite ended the session with Coupons.com rising 7.3% to $147.66 on Thursday, following the last session’s downward trend. NASDAQ Composite jumped 0.05% to $14,942.83, after three consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for Coupons.com is 2275850 which is 34.77% above its average volume of 1688590.

Coupons.com’s last close was $150.84, 59.99% below its 52-week high of $377.04.

The company’s growth estimates for the present quarter and the next is a negative 88.9% and a negative 135.3%, respectively.

Coupons.com’s Revenue

Year-on-year quarterly revenue growth grew by 42.3%, now sitting on 642.68M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Coupons.com’s stock is considered to be oversold (<=20).

Coupons.com’s Stock Yearly Top and Bottom Value

Coupons.com’s stock is valued at $147.66 at 16:32 EST, under its 52-week low of $154.22.

Coupons.com’s Moving Average

Coupons.com’s worth is way under its 50-day moving average of $219.20 and way below its 200-day moving average of $237.78.

More news about Coupons.com.

8. Vericel Corporation (VCEL) – 6.74%

NASDAQ Composite ended the session with Vericel Corporation rising 6.74% to $38.94 on Thursday, after two sequential sessions in a row of losses. NASDAQ Composite rose 0.05% to $14,942.83, after three successive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for Vericel Corporation is 560655 which is 25.47% above its average volume of 446819.

Vericel Corporation’s last close was $36.25, 47.42% under its 52-week high of $68.94.

Vericel Corporation’s Sales

Vericel Corporation’s sales growth is 12.4% for the ongoing quarter and 32.1% for the next. The company’s growth estimates for the current quarter is a negative 32% and positive 57.1% for the next.

Vericel Corporation’s Revenue

Year-on-year quarterly revenue growth grew by 7%, now sitting on 153.82M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Vericel Corporation’s stock is considered to be overbought (>=80).

Vericel Corporation’s Stock Yearly Top and Bottom Value

Vericel Corporation’s stock is valued at $38.94 at 16:32 EST, way under its 52-week high of $68.94 and way above its 52-week low of $34.00.

Vericel Corporation’s Moving Average

Vericel Corporation’s value is below its 50-day moving average of $40.35 and way under its 200-day moving average of $50.44.

More news about Vericel Corporation.

9. Novavax (NVAX) – 6.54%

NASDAQ Composite ended the session with Novavax jumping 6.54% to $134.99 on Thursday, after two sequential sessions in a row of losses. NASDAQ Composite jumped 0.05% to $14,942.83, after three successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for Novavax is 6191600 which is 2.88% above its average volume of 6017910.

Novavax’s last close was $130.17, 60.75% under its 52-week high of $331.68.

The company’s growth estimates for the present quarter is a negative 21.8% and positive 213.7% for the next.

Novavax’s Revenue

Year-on-year quarterly revenue growth grew by 13.9%, now sitting on 1.2B for the twelve trailing months.

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $134.99 at 16:32 EST, way below its 52-week high of $331.68 and way above its 52-week low of $107.08.

Novavax’s Moving Average

Novavax’s value is way under its 50-day moving average of $170.98 and way under its 200-day moving average of $193.54.

More news about Novavax.

10. Bilibili (BILI) – 6.37%

NASDAQ Composite ended the session with Bilibili jumping 6.37% to $40.89 on Thursday while NASDAQ Composite rose 0.05% to $14,942.83.

Volume

Today’s last reported volume for Bilibili is 8005700 which is 44.9% above its average volume of 5524660.

Bilibili’s last close was $41.70, 73.55% below its 52-week high of $157.66.

Bilibili’s Sales

Bilibili’s sales growth is 61.3% for the current quarter and 52.5% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 52.4% and a negative 75.9%, respectively.

Bilibili’s Revenue

Year-on-year quarterly revenue growth grew by 71.7%, now sitting on 15.46B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Bilibili’s stock is considered to be oversold (<=20).

Bilibili’s Stock Yearly Top and Bottom Value

Bilibili’s stock is valued at $40.89 at 16:32 EST, below its 52-week low of $43.88.

Bilibili’s Moving Average

Bilibili’s value is way under its 50-day moving average of $73.48 and way under its 200-day moving average of $91.08.

More news about Bilibili.

Most Active Losers Today

1. Amicus Therapeutics (FOLD) – -17.18%

NASDAQ Composite ended the session with Amicus Therapeutics falling 17.18% to $9.45 on Thursday, after two sequential sessions in a row of gains. NASDAQ Composite jumped 0.05% to $14,942.83, after three sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for Amicus Therapeutics is 10587700 which is 326.13% above its average volume of 2484570.

Amicus Therapeutics’s last close was $10.13, 60.1% below its 52-week high of $25.39.

The company’s growth estimates for the current quarter and the next is 28% and 33.3%, respectively.

Amicus Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 24.2%, now sitting on 281.82M for the twelve trailing months.

Amicus Therapeutics’s Stock Yearly Top and Bottom Value

Amicus Therapeutics’s stock is valued at $9.45 at 16:32 EST, way under its 52-week high of $25.39 and higher than its 52-week low of $8.60.

Amicus Therapeutics’s Moving Average

Amicus Therapeutics’s value is way below its 50-day moving average of $11.12 and below its 200-day moving average of $10.29.

More news about Amicus Therapeutics.

2. Take-Two Interactive Software (TTWO) – -13.13%

NASDAQ Composite ended the session with Take-Two Interactive Software sliding 13.13% to $142.99 on Thursday, after two consecutive sessions in a row of gains. NASDAQ Composite jumped 0.05% to $14,942.83, after three successive sessions in a row of gains, on what was a somewhat up trend trading session today.

Volume

Today’s last reported volume for Take-Two Interactive Software is 9842220 which is 569.04% above its average volume of 1471080.

Take-Two Interactive Software’s last close was $156.06, 27.38% below its 52-week high of $214.91.

The company’s growth estimates for the present quarter is a negative 33.5% and positive 4% for the next.

Take-Two Interactive Software’s Revenue

Year-on-year quarterly revenue growth grew by 2%, now sitting on 3.37B for the twelve trailing months.

Take-Two Interactive Software’s Stock Yearly Top and Bottom Value

Take-Two Interactive Software’s stock is valued at $142.99 at 16:32 EST, under its 52-week low of $144.58.

Take-Two Interactive Software’s Moving Average

Take-Two Interactive Software’s value is way under its 50-day moving average of $173.90 and way under its 200-day moving average of $170.91.

More news about Take-Two Interactive Software.

3. ATA Creativity Global (AACG) – -12.23%

NASDAQ Composite ended the session with ATA Creativity Global sliding 12.23% to $2.01 on Thursday while NASDAQ Composite rose 0.05% to $14,942.83.

Volume

Today’s last reported volume for ATA Creativity Global is 516504 which is 20.38% below its average volume of 648771.

ATA Creativity Global’s last close was $2.01, 89.82% below its 52-week high of $19.75.

ATA Creativity Global’s Revenue

Year-on-year quarterly revenue growth grew by 31%, now sitting on 190.5M for the twelve trailing months.

ATA Creativity Global’s Stock Yearly Top and Bottom Value

ATA Creativity Global’s stock is valued at $2.01 at 16:32 EST, way below its 52-week high of $19.75 and way higher than its 52-week low of $1.00.

ATA Creativity Global’s Moving Average

ATA Creativity Global’s value is way above its 50-day moving average of $1.74 and way below its 200-day moving average of $2.60.

More news about ATA Creativity Global.

4. AGBA Acquisition Limited (AGBAR) – -11.59%

NASDAQ Composite ended the session with AGBA Acquisition Limited sliding 11.59% to $0.15 on Thursday, after five consecutive sessions in a row of losses. NASDAQ Composite rose 0.05% to $14,942.83, after three successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

AGBA Acquisition Limited’s last close was $0.19, 23.09% higher than its 52-week high of $0.15.

AGBA Acquisition Limited’s Stock Yearly Top and Bottom Value

AGBA Acquisition Limited’s stock is valued at $0.15 at 16:32 EST, under its 52-week low of $0.15.

More news about AGBA Acquisition Limited.

5. Celsius Holdings (CELH) – -8.96%

NASDAQ Composite ended the session with Celsius Holdings sliding 8.96% to $49.71 on Thursday, following the last session’s downward trend. NASDAQ Composite jumped 0.05% to $14,942.83, after three successive sessions in a row of gains, on what was a somewhat up trend trading session today.

Volume

Today’s last reported volume for Celsius Holdings is 3317650 which is 223.44% above its average volume of 1025730.

Celsius Holdings’s last close was $52.12, 52.71% below its 52-week high of $110.22.

Celsius Holdings’s Revenue

Year-on-year quarterly revenue growth grew by 116.6%, now sitting on 187.61M for the twelve trailing months.

Celsius Holdings’s Stock Yearly Top and Bottom Value

Celsius Holdings’s stock is valued at $49.71 at 16:32 EST, way below its 52-week high of $110.22 and way higher than its 52-week low of $35.40.

Celsius Holdings’s Moving Average

Celsius Holdings’s worth is way under its 50-day moving average of $86.33 and way under its 200-day moving average of $71.70.

More news about Celsius Holdings.

6. Accolade (ACCD) – -8.51%

NASDAQ Composite ended the session with Accolade falling 8.51% to $19.14 on Thursday while NASDAQ Composite jumped 0.05% to $14,942.83.

Volume

Today’s last reported volume for Accolade is 1686700 which is 109.22% above its average volume of 806157.

Accolade’s last close was $21.23, 64.58% under its 52-week high of $59.93.

The company’s growth estimates for the present quarter and the next is a negative 131.2% and a negative 68.2%, respectively.

Accolade’s Revenue

Year-on-year quarterly revenue growth grew by 99.2%, now sitting on 230.49M for the twelve trailing months.

Accolade’s Stock Yearly Top and Bottom Value

Accolade’s stock is valued at $19.14 at 16:32 EST, way below its 52-week high of $59.93 and above its 52-week low of $18.72.

Accolade’s Moving Average

Accolade’s worth is way under its 50-day moving average of $28.19 and way under its 200-day moving average of $41.97.

More news about Accolade.

7. VBI Vaccines (VBIV) – -8.02%

NASDAQ Composite ended the session with VBI Vaccines falling 8.02% to $1.95 on Thursday while NASDAQ Composite jumped 0.05% to $14,942.83.

Volume

Today’s last reported volume for VBI Vaccines is 5877640 which is 68.27% above its average volume of 3492950.

VBI Vaccines’s last close was $2.09, 56.73% under its 52-week high of $4.83.

VBI Vaccines’s Sales

VBI Vaccines’s sales growth is a negative 14.6% for the present quarter and 265.4% for the next.

VBI Vaccines’s Revenue

Year-on-year quarterly revenue growth declined by 64.1%, now sitting on 714k for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

VBI Vaccines’s stock is considered to be oversold (<=20).

VBI Vaccines’s Stock Yearly Top and Bottom Value

VBI Vaccines’s stock is valued at $1.95 at 16:32 EST, way under its 52-week high of $4.83 and above its 52-week low of $1.86.

VBI Vaccines’s Moving Average

VBI Vaccines’s worth is way below its 50-day moving average of $2.63 and way under its 200-day moving average of $3.04.

More news about VBI Vaccines.

8. XTL Biopharmaceuticals Ltd. (XTLB) – -7.71%

NASDAQ Composite ended the session with XTL Biopharmaceuticals Ltd. sliding 7.71% to $2.65 on Thursday, following the last session’s downward trend. NASDAQ Composite rose 0.05% to $14,942.83, after three successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for XTL Biopharmaceuticals Ltd. is 1998 which is 92.68% below its average volume of 27303.

XTL Biopharmaceuticals Ltd.’s last close was $2.65, 60.39% under its 52-week high of $6.69.

XTL Biopharmaceuticals Ltd.’s Stock Yearly Top and Bottom Value

XTL Biopharmaceuticals Ltd.’s stock is valued at $2.65 at 16:32 EST, way below its 52-week high of $6.69 and above its 52-week low of $2.56.

XTL Biopharmaceuticals Ltd.’s Moving Average

XTL Biopharmaceuticals Ltd.’s worth is way under its 50-day moving average of $3.13 and way below its 200-day moving average of $3.61.

More news about XTL Biopharmaceuticals Ltd..

9. Adial Pharmaceuticals (ADILW) – -7.48%

NASDAQ Composite ended the session with Adial Pharmaceuticals dropping 7.48% to $0.62 on Thursday while NASDAQ Composite jumped 0.05% to $14,942.83.

Adial Pharmaceuticals’s last close was $0.62, 12.03% below its 52-week high of $0.70.

Adial Pharmaceuticals’s Stock Yearly Top and Bottom Value

Adial Pharmaceuticals’s stock is valued at $0.62 at 16:32 EST, below its 52-week low of $0.62.

More news about Adial Pharmaceuticals.

10. Allakos (ALLK) – -7.39%

NASDAQ Composite ended the session with Allakos dropping 7.39% to $7.89 on Thursday while NASDAQ Composite jumped 0.05% to $14,942.83.

Volume

Today’s last reported volume for Allakos is 1703680 which is 57.41% below its average volume of 4000900.

Allakos’s last close was $8.14, 94.85% below its 52-week high of $157.98.

The company’s growth estimates for the present quarter is a negative 37.2% and positive 18.3% for the next.

Allakos’s Stock Yearly Top and Bottom Value

Allakos’s stock is valued at $7.89 at 16:32 EST, way below its 52-week high of $157.98 and above its 52-week low of $7.76.

Allakos’s Moving Average

Allakos’s worth is way under its 50-day moving average of $60.28 and way below its 200-day moving average of $87.19.

More news about Allakos.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here